Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 11/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12233680 | 1.00 | SLC18A3 (0.74) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL8989794 | 1.00 | SLC18A3 (0.74) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL29075879 | 1.00 | SLC18A3 (0.74) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL17286254 | 1.00 | SLC18A3 (0.74) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL14367947 | 1.00 | SLC18A3 (0.74) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL25305403 | 1.00 | SLC18A3 (0.74) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL4488178 | 1.00 | SLC18A3 (0.74) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL4488180 | 1.00 | SLC18A3 (0.74) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL11346322 | 0.97 | SLC18A3 (0.72) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL6597975 | 0.97 | SLC18A3 (0.72) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179233-A1 | PROCESS AND CATALYSTS FOR HYDROGEN MEDIATED ANIONIC COPOLYMERIZATION OF CONJUGATED DIENES AND LIQUID COPOLYMERS THEREOF | ALBEMARLE CORPORATION (US) | 2025-06-05 | — | — | US | disclosed |
| EP-4486808-A2 | PROCESS AND CATALYSTS FOR HYDROGEN MEDIATED ANIONIC COPOLYMERIZATION OF CONJUGATED DIENES AND LIQUID COPOLYMERS THEREOF | ALBEMARLE CORPORATION (US) | 2025-01-08 | — | — | EP | disclosed |
| CN-119137172-A | Process and catalyst for hydrogen-mediated anionic copolymerization of conjugated dienes and liquid copolymers thereof | 雅宝公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240034825-A1 | PROCESS AND CATALYSTS FOR HYDROGEN MEDIATED ANIONIC POLYMERIZATION OF CONJUGATED DIENES AND LIQUID POLYMERS THEREOF | ALBEMARLE CORPORATION | 2024-02-01 | — | — | US | disclosed |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2024-01-18 | — | — | US | disclosed |
| WO-2023168218-A2 | PROCESS AND CATALYSTS FOR HYDROGEN MEDIATED ANIONIC COPOLYMERIZATION OF CONJUGATED DIENES AND LIQUID COPOLYMERS THEREOF | ALBEMARLE CORPORATION (US) | 2023-09-07 | — | — | WO | disclosed |
| CN-116568675-A | Cyclic isothiourea derivatives as CXCR4 modulators | 埃尔米乌治疗公司 | 2023-08-08 | — | — | CN | disclosed |
| EP-4217353-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | Ermium Therapeutics (FR) | 2023-08-02 | — | — | EP | disclosed |
| CN-116368159-A | Process and catalyst for hydrogen-mediated anionic polymerization of conjugated dienes and liquid polymers thereof | 雅宝公司 | 2023-06-30 | — | — | CN | disclosed |
| WO-2022064075-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2022-03-31 | — | — | WO | disclosed |
| WO-1999050225-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | NORTRAN PHARMACEUTICALS INC. (CA) | 1999-10-07 | — | — | WO | disclosed |
| WO-1999015521-A1 | BENZOTHIOPHENES | ELI LILLY AND COMPANY (US) | 1999-04-01 | — | — | WO | disclosed |
| EP-0905132-A1 | Benzothiophenes | ELI LILLY AND COMPANY (US) | 1999-03-31 | — | — | EP | disclosed |
| US-5885984-A | BLOCKADE OF ION CHANNELS AND THE TREATMENT OF ARRHYTHMIAS. | UNIVERSITY OF BRITISH COLUMBIA (CA) | 1999-03-23 | — | — | US | disclosed |
| EP-0863755-A4 | ANTITHROMBOTIC DIAMINES | LILLY CO ELI (US) | 1999-01-20 | — | — | EP | disclosed |
| EP-0863755-A1 | ANTITHROMBOTIC DIAMINES | ELI LILLY AND COMPANY (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997025033-A1 | ANTITHROMBOTIC DIAMINES | ELI LILLY AND COMPANY (US) | 1997-07-17 | — | — | WO | disclosed |
| US-5637583-A | ANTIARRHYTHMIA AGENTS | UNIVERSITY OF BRITISH COLUMBIA (CA) | 1997-06-10 | — | — | US | disclosed |
| EP-0720605-A1 | AMINOCYCLOHEXYLESTERS AND USES THEREOF | UNIVERSITY OF BRITISH COLUMBIA (CA) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995008544-A1 | AMINOCYCLOHEXYLESTERS AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1995-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | CXCR4, CXCR1, CXCL12 | SLC18A3 1097/4885CYP2D6 4214/4885TSHR 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.